Efficacy and toxicity of eribulin treatment in metastatic breast cancer patients

Acta Oncol. 2019 Jan;58(1):119-121. doi: 10.1080/0284186X.2018.1497301. Epub 2018 Aug 11.

Authors

Anne Sofie Brems-Eskildsen¹, Kristina Bak Kristoffersen², Søren Linnet³, Tamás Lörincz², Sven Tyge Langkjer¹

Affiliations

¹ a Department of Oncology , University Hospital of Aarhus , Aarhus C , Denmark.
² b Department of Oncology , University Hospital of Aalborg , Aalborg , Denmark.
³ c Department of Oncology , Regional Hospital West Jutland , Herning , Denmark.

PMID: 30101626
DOI: 10.1080/0284186X.2018.1497301

No abstract available

Publication types

Letter
Systematic Review

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / mortality
Carcinoma, Ductal, Breast / drug therapy*
Carcinoma, Ductal, Breast / mortality
Carcinoma, Lobular / drug therapy*
Carcinoma, Lobular / mortality
Female
Furans / therapeutic use*
Humans
Kaplan-Meier Estimate
Ketones / therapeutic use*
Middle Aged
Retrospective Studies
Treatment Outcome

Substances

Antineoplastic Agents
Furans
Ketones
eribulin